Press Releases

Press Releases

Search by keywords:

189 Press Releases found

Experimental Treatment Could Improve Stem Cell Transplants

A Memorial Sloan Kettering Cancer Center study suggests that a new, experimental treatment could make bone marrow and stem cell transplantation more effective and safe.

  • Saturday, December 10, 2011

Researchers Discover Why New Melanoma Drug Stops Working

Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug, vemurafenib.

  • Wednesday, November 23, 2011

City of Hope and Memorial Sloan Kettering Receive NCI Grant to Train Nurses Caring for Cancer Survivors

A five-year grant of more than $1.4 million will fund a program to train nurses in helping survivors achieve the best possible quality of life after cancer.

  • Monday, October 17, 2011

Three Young Investigators Named Winners of Paul Marks Prize for Cancer Research

Memorial Sloan Kettering Cancer Center will recognize three young investigators for their exceptional bodies of innovative work that has helped to advance the field of cancer research. The researchers will receive the Paul Marks Prize for Cancer Research, an award presented biennially by Memorial Sloan Kettering to honor promising scientists under the age of 46.

  • Tuesday, September 20, 2011

Gene Mutation Contributes To Leukemia By Enhancing Function Of Blood Stem Cells

Memorial Sloan Kettering researchers helped to identify a key insight into what first goes wrong in the development of many leukemias.

  • Thursday, June 30, 2011

First Comprehensive Analysis Of Gene Mutations In Ovarian Cancer Brings Patients One Step Closer To Personalized Medicine

According to a large-scale genomic analysis of the most common and aggressive type of ovarian cancer, researchers from Memorial Sloan- Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) project identified genetic mutations and pathways that distinctly set the disease apart not only from other types of ovarian cancer, but from other solid tumors as well.

  • Wednesday, June 29, 2011

Breast Cancer Treatment Shows Benefit For Women With Small, Localized Disease

Memorial Sloan Kettering Cancer Center physician-scientists report that women with small, node-negative, HER2-positive breast cancer may obtain a significant benefit from adjuvant chemotherapy with trastuzumab (Herceptin®), a drug previously shown to improve outcomes in advanced cancer and prevent the return of cancer in women diagnosed with higher-risk, early-stage, HER2-positive breast cancer. This study appears online in the journal Cancer, and will be published in a future print edition.

  • Friday, June 24, 2011

Groundbreaking Advances In The Treatment Of Advanced Melanoma Led By Physician-Researchers At Memorial Sloan Kettering Cancer Center

In an extraordinary demonstration of excellence, positive results from two separate studies of new therapies for the treatment of advanced melanoma were presented at the plenary session of the 2011 annual meeting of the American Society of Clinical Oncology by Paul Chapman, MD, and Jedd Wolchok MD, PhD, members of Memorial Sloan Kettering Cancer Center's Melanoma and Sarcoma service, and lead authors on the studies along with collaborators from more than a one hundred cancer centers worldwide.

  • Sunday, June 5, 2011

Drug Shown To Significantly Improve Survival In Men With Metastatic Prostate Cancer While Exploring A Potential Biomarker To Measure Treatment Response

The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are exploring a potential biomarker of response to treatment in general.

  • Saturday, June 4, 2011

New Drug Combination Slows Tumor Growth For Recurrent Ovarian Cancer

Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

  • Saturday, June 4, 2011